返回 Agenda
Artificial Intelligence Enhanced Data Analytics for Clinical Trials
Session Chair(s)
Felix Frueh, PHD
Executive Partner
Opus Three LLC, United States
Artificial Intelligence (AI) enhanced drug development is becoming increasingly important in the era of precision medicine.This session illustrates with examples how AI can impact and facilitate modern drug development.
Learning Objective : Recognize the benefit of using artificial intelligence (AI) approaches in modern drug development; Identify the regulatory paths using biomarker-based, AI-enhanced strategies in clinical trials; Outline how to incorporate advanced analytics into trial analyses and future trial designs.
Speaker(s)
Panelist
Mohammad Afshar, MD, PHD
Ariana Pharma, United States
Chief Executive Officer
Panelist
Federico Manuel Goodsaid, PHD
Ariana Pharma, United States
Senior Vice President, Regulatory Affairs